Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383535 | 0.70 | KDM4E (0.39) | KDM4EGPR3 | |
| SCHEMBL976367 | 0.68 | KDM4E (0.40) | KDM4EGPR3 | |
| SCHEMBL6622101 | 0.67 | KDM4E (0.39) | KDM4EGPR3 | |
| SCHEMBL28262113 | 0.67 | KDM4E (0.39) | KDM4EGPR3 | |
| SCHEMBL378548 | 0.67 | KDM4E (0.39) | KDM4EGPR3 | |
| SCHEMBL30343302 | 0.67 | KDM4E (0.39) | KDM4EGPR3 | |
| SCHEMBL28080700 | 0.66 | KDM4E (0.38) | KDM4EGPR3 | |
| SCHEMBL29176096 | 0.66 | KDM4E (0.38) | KDM4EGPR3 | |
| SCHEMBL27619154 | 0.66 | KDM4E (0.38) | KDM4EGPR3 | |
| SCHEMBL27619538 | 0.66 | KDM4E (0.38) | KDM4EGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | claimed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | claimed |
| EP-1044197-A2 | NEW PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-10-18 | — | — | EP | claimed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-0748805-B1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO (JP) | 1998-04-08 | — | — | EP | claimed |
| EP-0748805-A1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-18 | — | — | EP | claimed |
| CN-117186081-A | Main body material and preparation method thereof, double main body material and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116496294-B | Main body material and preparation method thereof, double main body material and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116496294-A | Main body material and preparation method thereof, double main body material and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | SEIKAGAKU CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| CN-1214073-A | Ferroelectric liquid crystal mixture | HOECHST AG (DE) | 1999-04-14 | — | — | CN | disclosed |
| EP-0748805-B1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0748805-A1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | HCAR1, HCAR2, MCCC2 | KDM4E 1836/4885GPR3 1252/4885 |
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | ALG1, NGLY1, SAT1 | KDM4E 2708/4885GPR3 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.